Help us: Donate
Follow us on:
×

Menu

Back

Tag: Investment

Oisin Logo
Today, Oisín Biotechnologies, a well-known developer of senolytics, drugs that destroy harmful senescent cells, has announced that it has more than doubled its total funding through an oversubscribed round. This has taken its total funding from $4.5 million to $9.5 million. Why we Age: Cellular SenescenceAs your body ages, more of your cells become senescent....
VitaDAO
VitaDAO wants to democratize biotech VitaDAO will aim to fund longevity research, give its members ownership of the resulting IP, and allow members to vote on the direction of the organization. Few would argue that the drug development process is efficient. Even as the technology surrounding the process gets better and cheaper, the time and...
Maximon logo
We kick off the week with some news from Switzerland and introduce the new longevity biotech company builder Maximon. The enthusiasm for technologies to promote longevity and even increase healthy human lifespan seems to be rising in Switzerland. There are frequently articles in the popular press about the topic and we were even asked to...
Bold logo
Thanks to an injection of seed round cash, a new company, Bold, joins the growing pool of organizations that are focused on wellness and disease prevention. The rising interest in wellness and healthy aging It’s no secret that the interest in digital health and wellness has risen in recent years along with the popularity of...
Interview image for Tina Woods
Tina Woods is a UK-based founder of several social enterprises in healthcare and longevity and the author of the book Live Longer with AI, which we recently reviewed. In this interview, Tina shares valuable insights on how social entrepreneurship works in our field, what governments can and must do to promote healthy aging, and what...
Dr. Tyler Golato
In this presentation given at Ending Age-Related Diseases 2020, Dr. Tyler Golato talked about his company, Molecule, highlighting the current problems with pharmaceutical development and offering a new, decentralized method of developing therapies. He discussed the well-known valley of death, the gap between the basic research of academia and the later-stage development of pharmaceutical companies....